BSX Financial Facts
Goodwill impairment charge: 0Contingent consideration expense: 6M
See Full Income Statement
Other long-term liabilities: 1.98B
Accumulated other comprehensive loss, net of tax: -132M
See Full Balance Sheet
Boston Scientific (BSX) Earnings
|
Expand Research on BSX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +3.2% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +0.4% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7/27/22 |  |
Q222 | N/A | $0.43 | N/A | N/A | $3.23B | N/A | N/A | N/A | |
| 4/27/22 | |
Q122 | $0.39 | $0.39 | $0.00 | $3.03B | $2.95B | N/A |  | | Details |
| 2/2/22 | |
Q421 | $0.45 | $0.44 | +$0.01 | $3.13B | $3.11B | N/A | | | Details |
| 10/27/21 | |
Q321 | $0.41 | $0.40 | +$0.01 | $2.93B | $2.97B | N/A | | | Details |
| 7/27/21 | |
Q221 | $0.40 | $0.37 | +$0.03 | $3.08B | $2.94B | N/A | | | Details |
| 4/28/21 | |
Q121 | $0.37 | $0.31 | +$0.06 | $2.75B | $2.62B | N/A | | | Details |
| 10/28/20 | |
Q320 | $0.37 | $0.25 | +$0.12 | $2.67B | $2.52B | N/A | | | Details |
| 7/29/20 | |
Q220 | $0.08 | -$0.02 | +$0.10 | $2B | $1.73B | N/A | | | Details |
